- Home
- Clinical Trials
Healthy volunteers studies Auckland (1)
Hebe Healthy Volunteers Study Auckland
Auckland
Please note that this study has now closed. However, we encourage you to pre-register your interest for upcoming clinical research studies here.
Description
What to expect
Study details
Ages
18-65
Duration
The study duration is up to 52 weeks, including a screening period of up to 28 days, a single dosing day, and follow-up appointments through to Day 337. Participation includes a screening visit, an inpatient stay from Day -1 through completion of Day 4 assessments, and around 11 outpatient follow-up visits.
Compensation
Participants will be paid for time and study-related costs.
Eligibility Criteria
You may qualify for this study if you:
- Are male or female and aged 18 to 65 years
- Are healthy based on medical history, physical examination, ECG, vital signs and screening laboratory tests
- Have a body mass index (BMI) of at least 18.5 and less than 32.5 kg/m²
- Weigh at least 45 kg and no more than 100 kg
- Are willing and able to comply with study requirements, including contraception requirements where applicable
- Are willing and able to stay four nights at our clinic facility
Other criteria may apply.
Locations
Description
ZL-1503 is an investigational antibody being developed as a potential future medicine for moderate-to-severe atopic dermatitis. Atopic dermatitis is a chronic skin condition that can involve itch, skin lesions, discomfort and reduced quality of life.
This study is being conducted in healthy volunteers to evaluate the pharmacokinetics, safety, tolerability and immune response to ZL-1503 after one subcutaneous or intravenous dose.
Please note, our next admission dates for this study are as follows:
- Cohort 2B | 28 September 2026
- Cohort 3A | 29 September 2026
- Cohort 3B | 11 October 2026
What to expect
If you choose to take part and are eligible, you will be randomly assigned to receive a single dose of ZL-1503 by either intravenous infusion or subcutaneous injection. Study assessments will include informed consent, medical history, physical examinations, vital signs, ECGs, pregnancy testing where applicable, blood and urine tests, pharmacokinetic and immunogenicity blood sampling, and monitoring for side effects. You will stay at the clinical research unit from the day before dosing through Day 4 assessments and then return for follow-up visits up to Day 337.
Please note that this study has now closed. However, we encourage you to pre-register your interest for upcoming clinical research studies here.